OBJECTIVES: The aim of the study was to estimate the rates of cardiovascular disease (CVD) events after stopping smoking in patients with HIV infection. METHODS: Patients who reported smoking status and no previous CVD prior to enrolment in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study were included in this study. Smoking status is collected at each visit as current smoker (yes/no) and ever smoker (yes/no). Time since stopping smoking was calculated for persons who had reported current smoking during follow-up and no current smoking subsequently. Endpoints were: myocardial infarction (MI); coronary heart disease (CHD: MI plus invasive coronary artery procedure or death from other CHD); CVD (CHD plus carotid artery endarterectomy or stroke); and all-cause mortality. Event rates were calculated for never, previous and current smokers, and smokers who stopped during follow-up. Incidence rate ratios (IRRs) were determined using Poisson regression adjusted for age, sex, cohort, calendar year, family history of CVD, diabetes, lipids, blood pressure and antiretroviral treatment. RESULTS: A total of 27 136 patients had smoking status reported, with totals of 432, 600, 746 and 1902 MI, CHD, CVD and mortality events, respectively. The adjusted IRR of CVD in patients who stopped smoking during follow-up decreased from 2.32 within the first year of stopping to 1.49 after >3 years compared with those who never smoked. Similar trends were observed for the MI and CHD endpoints. Reductions in risk were less pronounced for all-cause mortality. CONCLUSION: The risk of CVD events in HIV-positive patients decreased with increasing time since stopping smoking. Smoking cessation efforts should be a priority in the management of HIV-positive patients.
OBJECTIVES: The aim of the study was to estimate the rates of cardiovascular disease (CVD) events after stopping smoking in patients with HIV infection. METHODS:Patients who reported smoking status and no previous CVD prior to enrolment in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study were included in this study. Smoking status is collected at each visit as current smoker (yes/no) and ever smoker (yes/no). Time since stopping smoking was calculated for persons who had reported current smoking during follow-up and no current smoking subsequently. Endpoints were: myocardial infarction (MI); coronary heart disease (CHD: MI plus invasive coronary artery procedure or death from other CHD); CVD (CHD plus carotid artery endarterectomy or stroke); and all-cause mortality. Event rates were calculated for never, previous and current smokers, and smokers who stopped during follow-up. Incidence rate ratios (IRRs) were determined using Poisson regression adjusted for age, sex, cohort, calendar year, family history of CVD, diabetes, lipids, blood pressure and antiretroviral treatment. RESULTS: A total of 27 136 patients had smoking status reported, with totals of 432, 600, 746 and 1902 MI, CHD, CVD and mortality events, respectively. The adjusted IRR of CVD in patients who stopped smoking during follow-up decreased from 2.32 within the first year of stopping to 1.49 after >3 years compared with those who never smoked. Similar trends were observed for the MI and CHD endpoints. Reductions in risk were less pronounced for all-cause mortality. CONCLUSION: The risk of CVD events in HIV-positivepatients decreased with increasing time since stopping smoking. Smoking cessation efforts should be a priority in the management of HIV-positivepatients.
Authors: Gary M Clifford; Jerry Polesel; Martin Rickenbach; Luigino Dal Maso; Olivia Keiser; Andreas Kofler; Elisabetta Rapiti; Fabio Levi; Gernot Jundt; Thomas Fisch; Andrea Bordoni; Daniel De Weck; Silvia Franceschi Journal: J Natl Cancer Inst Date: 2005-03-16 Impact factor: 13.506
Authors: D N Burns; D Hillman; J D Neaton; R Sherer; T Mitchell; L Capps; W G Vallier; M D Thurnherr; F M Gordin Journal: J Acquir Immune Defic Syndr Hum Retrovirol Date: 1996-12-01
Authors: W T Caiaffa; D Vlahov; N M Graham; J Astemborski; L Solomon; K E Nelson; A Muñoz Journal: Am J Respir Crit Care Med Date: 1994-12 Impact factor: 21.405
Authors: T C Do; D Boettiger; M Law; S Pujari; F Zhang; R Chaiwarith; S Kiertiburanakul; M P Lee; R Ditangco; W W Wong; K V Nguyen; T P Merati; T T Pham; A Kamarulzaman; S Oka; E Yunihastuti; N Kumarasamy; P Kantipong; J Y Choi; O T Ng; N Durier; K Ruxrungtham Journal: HIV Med Date: 2016-08 Impact factor: 3.180
Authors: Qu Cui; Linda Robinson; Dawn Elston; Fiona Smaill; Jeffrey Cohen; Corinna Quan; Nancy McFarland; Lehana Thabane; Andrew McIvor; Johannes Zeidler; Marek Smieja Journal: AIDS Patient Care STDS Date: 2011-10-18 Impact factor: 5.078
Authors: Rimke Bijker; Nagalingeswaran Kumarasamy; Sasisopin Kiertiburanakul; Sanjay Pujari; Wilson Lam; Romanee Chaiwarith; Wing W Wong; Adeeba Kamarulzaman; Pacharee Kantipong; Anchalee Avihingsanon; Kinh V Nguyen; Junko Tanuma; Oon Tek Ng; Benedict Lh Sim; Tuti P Merati; Jun Y Choi; Rossana Ditangco; Evy Yunihastuti; Ly P Sun; Cuong D Do; Jeremy Ross; Matthew Law Journal: Antivir Ther Date: 2019
Authors: Matthew J Feinstein; Milana Bogorodskaya; Gerald S Bloomfield; Rajesh Vedanthan; Mark J Siedner; Gene F Kwan; Christopher T Longenecker Journal: Curr Cardiol Rep Date: 2016-11 Impact factor: 2.931
Authors: Julia E H Nolte; Till Neumann; Jennifer M Manne; Janet Lo; Anja Neumann; Sarah Mostardt; Suhny Abbara; Udo Hoffmann; Thomas J Brady; Juergen Wasem; Steven K Grinspoon; G Scott Gazelle; Alexander Goehler Journal: Eur J Prev Cardiol Date: 2013-03-28 Impact factor: 7.804
Authors: Wajiha Z Akhtar-Khaleel; Robert L Cook; Steve Shoptaw; Pamela J Surkan; Linda A Teplin; Ronald Stall; Rebecca J Beyth; Todd M Manini; Michael Plankey Journal: AIDS Behav Date: 2016-08